Home › Compare › SSTRF vs ABBV
SSTRF yields 2000000.00% · ABBV yields 3.06%● Live data
📍 SSTRF pulled ahead of the other in Year 1
Combined, SSTRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SSTRF + ABBV for your $10,000?
Silverstar Holdings Ltd., through its subsidiaries, publishes entertainment software worldwide. It publishes entertainment software for various game platforms, including Microsoft's Xbox 360 and Xbox platforms, Sony's PS2 and PSP platforms, Nintendo's Wii, and DS platforms, as well as personal computer, mobile, and other digital platforms. The company also develops wireless broadband solutions for the mobile telecommunications industry. Silverstar Holdings Ltd.'s games are sold directly in the United Kingdom; either directly or through third party software distributors in the rest of Europe; and through licensed third party distributors in North America. Its products are also sold on CD's and over the Internet. Silverstar Holdings Ltd. was formerly known as Leisureplanet Holdings, Ltd. and changed its name to Silverstar Holdings Ltd. in December 2000. The company was founded in 1995 and is based in Hamilton, Bermuda.
Full SSTRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.